Clinical characteristics, glycemic control & quality of life of patients using Android Artificial Pancreas System (AAPS) in Brazil.

OBJECTIVE

This study evaluated the safety and efficacy of the Android Artificial Pancreas System (AAPS) in Brazilians with type 1 diabetes mellitus (T1D).

SUBJECTS AND

METHODS

A total of 371 participants were surveyed, including 62 AAPS users and 309 non-users. AAPS configurations included continuous glucose monitoring (CGM ), Bluetooth transmitter (MiaoMiao), and a non-automated insulin pump.

RESULTS

AAPS users had a mean Time in Range (TIR) of 78.5% ± 16.6, with HbA1c levels decreasing from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001). Compared to non-AAPS users, AAPS users demonstrated better glycemic control, fewer severe hypoglycemic events (p = 0.006), and improved quality of life (p < 0.0001). However, 23.08% of AAPS users had a TIR below 70%, and time in level-2 hypoglycemia exceeded recommendations.

CONCLUSION

These findings highlight AAPS as a low-cost alternative to commercial systems, with potential to expand access to automated therapy globally, particularly in resource-limited settings.